LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington's disease.
LOQUS23 THERAPEUTICS has raised $46.4M in total funding. The most recent round was Series A. The last funding was announced in October 2024.
LOQUS23 THERAPEUTICS's investors include SV Health Investors, Dementia Discovery Fund, Forbion Capital Partners, Novartis Venture Fund.
LOQUS23 THERAPEUTICS is headquartered in London, United Kingdom.
LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington's disease.
LOQUS23 THERAPEUTICS is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"LOQUS23 THERAPEUTICS — Funding & Investors." VCBacked, October 2, 2024, https://www.vcbacked.co/company/loqus23-therapeutics. Accessed October 28, 2026.
VCBacked. (2024). LOQUS23 THERAPEUTICS — Funding & Investors. Retrieved October 28, 2026, from https://www.vcbacked.co/company/loqus23-therapeutics
{{cite web |title=LOQUS23 THERAPEUTICS — Funding & Investors |url=https://www.vcbacked.co/company/loqus23-therapeutics |website=VCBacked |access-date=October 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated